Lysosomal storage disorder biotech Gain Therapeutics prices IPO at $11 midpoint

Gain Therapeutics, a preclinical biotech developing small molecule therapies for lysosomal storage disorders, raised $40 million by offering 3.6 million shares at $11, within the range of $10 to $12. At pricing, the company commands a fully diluted market value of $129 million.Read More